Brand name drug companies are responsible for setting the prices of the prescription drugs in their portfolios. To maximize profits, at the expense of patients, taxpayers and the U.S. health care system, Big Pharma repeatedly hikes prices on existing products and sets increasingly outrageous launch prices on new medications.

Price-gouging, which leads to as many as one-in-three Americans experiencing financial hardship in affording prescription drugs, is enabled by Big Pharma’s egregious anti-competitive practices designed to extend monopolies and block patients from accessing more affordable alternatives, like generics and biosimilars.

Jan 30, 2025

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Johnson & Johnson Beats Wall Street Analysts’ Expectations Fueled by

Jan 27, 2025

BIG PHARMA WATCH: MERCK EXPEDITES ANTI-COMPETITIVE STRATEGY ON BLOCKBUSTER CANCER DRUG

Big Pharma Giant’s Patent Abuse Scheme for Keytruda Will Extend Monopoly